Stock VIRX VIRACTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Viracta Therapeutics, Inc.

Equities

VIRX

US92765F1084

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
0.8196 USD -0.17% Intraday chart for Viracta Therapeutics, Inc. -3.33% +43.79%
Apr. 15 Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial CI
Apr. 01 Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 136.2 55.77 22.02 32.19 - -
Enterprise Value (EV) 1 37.45 55.77 22.02 32.19 32.19 32.19
P/E ratio -1.01 x -1.12 x -0.43 x -0.71 x -0.73 x -0.89 x
Yield - - - - - -
Capitalization / Revenue - - - - 13.8 x 0.72 x
EV / Revenue - - - - 13.8 x 0.72 x
EV / EBITDA - - - - - -
EV / FCF -7,129,119 x - - - - -
FCF Yield -0% - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 37,312 38,197 38,625 39,272 - -
Reference price 2 3.650 1.460 0.5700 0.8196 0.8196 0.8196
Announcement Date 3/16/22 3/13/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 2.333 44.85
EBITDA - - - - - - -
EBIT 1 -12.06 -127.8 -50.59 -50.69 -59.91 -79.65 -49.07
Operating Margin - - - - - -3,413.43% -109.41%
Earnings before Tax (EBT) 1 - -114.8 -49.2 -51.06 -60.14 -79.75 -48.15
Net income 1 - -114.8 -49.2 -51.06 -62.41 -86.43 -67.77
Net margin - - - - - -3,704.18% -151.09%
EPS 2 -5.750 -3.600 -1.300 -1.320 -1.162 -1.120 -0.9167
Free Cash Flow - -19.1 - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 12/22/20 3/16/22 3/13/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - -
EBIT 1 -10.8 -11.32 -10.43 -10.5 -18.08 -11.57 -12.21 -12.45 -12.48 -13.56 -13.74 -14.5 -15.31 -16.36
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - -11.45 -10.55 -10.58 -17.74 -10.33 -12.21 -12.48 -12.6 -13.76 -13.8 -14.56 -15.37 -16.42
Net income 1 - -11.45 -10.55 -10.58 -17.74 -10.33 -12.21 -12.48 -12.6 -13.76 -14.13 -14.93 -15.85 -17.52
Net margin - - - - - - - - - - - - - -
EPS 2 - -0.3100 -0.2800 -0.2800 -0.4700 -0.2700 -0.3200 -0.3200 -0.3300 -0.3500 -0.3525 -0.3100 -0.2625 -0.2800
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/10/21 3/16/22 5/10/22 8/9/22 11/10/22 3/13/23 5/8/23 8/14/23 11/9/23 3/7/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position 98.7 - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow -19.1 - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 0.25 - 0.14 - - -
Capex / Sales - - - - - -
Announcement Date 3/16/22 3/13/23 3/7/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8196 USD
Average target price
7 USD
Spread / Average Target
+754.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VIRACTA THERAPEUTICS, INC. Stock Viracta Therapeutics, Inc.
+43.79% 32.24M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VIRX Stock
  4. Financials Viracta Therapeutics, Inc.